Article Text
Abstract
Objective: One of the factors leading to an invasive phenotype is the nm23 family of metastases-associated genes. Of the six known members, nm23-H1 is the most frequently studied potential anti-metastatic gene in cervical cancer. However, the possible molecular links to oncogenic human papillomavirus (HPV) are completely unexplored as yet.
Materials and methods: As a part of the HPV-Pathogen Istituto Superiore di Sanità study, a series of 150 squamous cell carcinomas (SCCs) and 152 cervical intraepithelial neoplasia (CIN) lesions were examined by immunohistochemical staining for nm23-H1, and tested for HPV by polymerase chain reaction (PCR) with three sets of primers (MY09/11, GP5+/GP6+ and short PCR fragment). Follow-up data were available on all patients with SCC, and 67 CIN lesions were monitored by serial PCR for clearance or persistence of HPV after cone treatment.
Results: A linear decrease (p = 0.001) was observed in nm23-H1 expression, starting from CIN1 (85% with normal expression), with the most dramatic down regulation on transition from CIN2 (70% normal) to CIN3 (39%) and further to SCC (25%). Reduced expression was associated with CIN3 or cancer at an odds ratio 8.72 (95% confidence interval 4.13 to 18.41). Nm23-H1 was of no use as a marker of the high-risk human papillomavirus (HR-HPV) type, and it did not predict clearance or persistence of HR-HPV after treatment of CIN. Importantly, nm23-H1 expression was a significant prognostic factor in cervical cancer, reduced expression being associated with lower survival (p = 0.022) in univariate analysis. In the multivariate (Cox) regression model, however, only the International Federation of Gynecology and Obstetrics stage (p = 0.001) and age (p = 0.011) remained independent prognostic predictors.
Conclusions: Down-regulated nm23-H1 expression is markedly associated with progression from CIN2 to CIN3, and predicts poor prognosis in cervical cancer. Nm23-H1 down regulation is probably orchestrated by mechanisms independent of HR-HPV oncoproteins and is possibly related to the emergence of a proteolytic phenotype.
- CIN, cervical intraepithelial neoplasia
- ERK, extracellular signal-regulated kinase
- FIGO, International Federation of Gynecology and Obstetrics
- HPV, oncogenic human papillomavirus
- HR-HPV, high-risk human papillomavirus
- IHC, immunohistochemistry
- ISS, Istituto Superiore di Sanità
- LR-HPV, low-risk human papillomavirus
- MMP, matrix metalloproteinase
- NDP, nucleoside diphosphate
- NPV, negative predictive value
- PCR, polymerase chain reaction
- PPV, positive predictive value
- SCC, squamous cell carcinoma
- VEGF, vascular endothelial growth factor
Statistics from Altmetric.com
- CIN, cervical intraepithelial neoplasia
- ERK, extracellular signal-regulated kinase
- FIGO, International Federation of Gynecology and Obstetrics
- HPV, oncogenic human papillomavirus
- HR-HPV, high-risk human papillomavirus
- IHC, immunohistochemistry
- ISS, Istituto Superiore di Sanità
- LR-HPV, low-risk human papillomavirus
- MMP, matrix metalloproteinase
- NDP, nucleoside diphosphate
- NPV, negative predictive value
- PCR, polymerase chain reaction
- PPV, positive predictive value
- SCC, squamous cell carcinoma
- VEGF, vascular endothelial growth factor
Footnotes
-
↵* HPV-Pathogen Istituto Superiore di Sanità Study Group: L Leoncini, M Alderisio—Unità Citoistopatologia, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità (ISS), Roma, Italy; M De Nuzzo—Dipertimento di Ginecologia e Ostetrica, Azienda Ospedaliera S Orsola Malpighi, Bologna, Italy; F Zanconati—UCO Anatomia Patologica, Istopatologia e Citodiagnostica, Ospedale Maggiore, Trieste, Italy; L Mariani, M Galati—Ginecologia e Ostetrica, IFO, Istituto Regina Elena, Rome, Italy; F Sesti, A Criscuolo, E Piccione—Isituto di Ginecologia, Università di Tor Vergata, Rome, Italy; A Agarossi, EA Casolati, M Valieri—Clinica Ostetrica e Ginecologia, Istituto Scienze Biomediche, Ospedale Luigi Sacco, Milano, Italy; M Galati, A di Carlo—IFO, Istituto San Gallicano, Unità Operativa MST/HIV, Rome, Italy.
-
Published Online First 14 March 2006
-
Competing interests: None declared.